Search results
Added:
1 year ago
In this short interview, Dr Joan Carles Trullas (Universitat de Vic-Central de Catalunya, ES) outlines the findings of the CLOROTIC trial, first presented at Heart Failure 2022.In this study, patients with decompensated heart failure were given a combined diuretic therapy using loop diuretics with thiazide diuretics to evaluate efficacy.
Discussion Points:
1. Background
2. Patient Cohort and…
View more
Added:
3 years ago
Introduction
Advances in heart failure medical therapy over the past few decades have improved the prognosis of patients with this condition. Despite this, heart failure remains a significant burden to the medical system as the incidence of heart failure hospitalisation continues to rise.1 Diuretics have been a mainstay of therapy in heart failure to relieve congestion and improve symptoms…
View more
Added:
1 year ago
SC Congress 22 — Late-breaker host, Dr Harriette Van Spall (McMaster University, CA) sat down with the principal investigator of the ADVOR trial (NCT03505788), Prof Wilfried Mullens (Hospital Oost-Limburg (ZOL), BE) to talk about the trial design and practical consideration in light of the new data.
ADVOR, a multi-center, randomized, double-blind clinical trial assessed the diuretic effects of…
View more
Added:
10 months ago
ESC-HFA 2023 – Prof John Cleland (University of Glasgow, Glasgow, UK) discusses the findings from a study that looked at the diagnostic of heart failure in a cohort of 1.1 million people using the NHS EMR database.
Finding presented at Heart Failure 2023, showed that more people treated with LD than receive diagnosis of heart failure, this disparity was greater in women compared to men.
…
View more
Added:
3 years ago
From Acute Heart Failure Towards Worsening or De Novo Heart Failure
The natural history of heart failure (HF) is characterised by disease progression and episodes of worsening HF and acute decompensation requiring outpatient treatment intensification, emergency department or in-hospital care.
Acute HF (AHF), also known as acute decompensated HF, is defined as a progressive and sometimes rapid…
View more
Added:
3 years ago
Approximately 90% of the more than 1 million yearly heart failure hospitalisations in the US and Europe are a result of symptoms and signs of fluid overload and are associated with readmission rates of 24% and 50% at 30 days and 6 months, respectively.1,2 Recurrent heart failure-related hospitalisations have uniformly been associated with worse outcomes, independent of age and renal function.3
…
View more
Added:
11 months ago
ESC-HFA 2023 — Dr Jasper Brugts (Thoraxcenter, NL) joins us to outline the findings and summarise the take-home messages from the MONITOR-HF trial (NTR7672).
MONITOR-HF was an open-label, randomised trial, done in 25 centres in the Netherlands. Eligible patients had chronic heart failure of New York Heart Association class III and a previous heart failure hospitalisation, irrespective of…
View more
Added:
3 years ago
Heart failure (HF) is one of the most common reasons for admission to hospital. It is associated with long in-patient stays, and has a high in-hospital and post-discharge morbidity and mortality, whether left ventricular ejection fraction (LVEF) is reduced (HFREF) or normal (HeFNEF).1,2 Congestion, or fluid overload, is a classic clinical feature of patients presenting with HF. In some patients,…
View more
Added:
10 months ago
ESC-HFA 23 — Dr Stephen Greene (Duke University School of Medicine, US) outlines the findings from the QoL study of the TRANSFORM-HF Trial (NCT03296813).
The TRANSFORM-HF trial is a randomized trial which compared torsemide to furosemide as a treatment for patients with heart failure. Around 2859 patients with heart failure were enrolled in the trial, whose clinical outcomes were measured across…
View more
Added:
1 year ago
AHA 22 - Late-breaker host, Dr Harriette Van Spall (McMaster University, CA) sits down with PI, Dr Robert J Mentz (Duke University of Medicine, US) to discuss the findings of the TRANSFORM-HF trial (NCT03296813).
This study aimed to compare the loop diuretics furosemide and torsemide in the treatment of patients with heart failure.Over 2800 patients were enrolled in the trial and were randomized…
View more
